echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Anti-Influenza Class 1 new drug of Anti-Influenza was approved for clinical use in China, accelerating the research and development of innovative drugs in the field of anti-infection

    Anti-Influenza Class 1 new drug of Anti-Influenza was approved for clinical use in China, accelerating the research and development of innovative drugs in the field of anti-infection

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Andi Kang (Wuxi) Co.
    , Ltd.
    independent research and development of biotechnology for the treatment and prevention of influenza, clinical trials of new drug candidates apply ADC189 of influenza B (IND), won the Chinese State Drug Administration Bureau Center for Drug Evaluation ( CDE) implied license
    .

    Andi Kang (Wuxi) Co.
    , Ltd.
    independent research and development of biotechnology for the treatment and prevention of influenza, clinical trials of new drug candidates apply ADC189 of influenza B (IND), won the Chinese State Drug Administration Bureau Center for Drug Evaluation (CDE) Implied permission
    .


    Andi Kang (Wuxi) Co.


    Infect

    ADC189 has a new anti-influenza mechanism, which can directly inhibit virus replication
    .


    It belongs to the Cap-dependent endonuclease inhibitor, which inhibits the CAP cap structure-dependent endonuclease in influenza virus


    Antikang Bio's design and development of ADC189 aims to combat influenza A and B viruses, including influenza strains resistant to oseltamivir and avian influenza strains (H7N9, H5N1)
    .


    The data of the "head-to-head" study shows that compared to another drug with the same target, ADC189 has the safety advantages of no central nervous system side effects, oral absorption is not affected by food, and a higher safe dose, showing "best- "in-class" characteristics


    Avian Influenza

    It is worth mentioning that a single oral dose of this new drug under development can block influenza virus replication within 24 hours
    .


    This is expected to bring great convenience to patients' medication


    According to Dr.
    Weiping Jiang, founder of Antikang Bio, the approval of ADC189 for clinical use is a milestone for the company
    .


    At present, the Antikang biological team has launched a phase 1 clinical study, led by top clinical experts in the field of anti-infection, to evaluate ADC189 for the treatment and prevention of influenza A and B in newborns, adolescents, adults, and the elderly.


    "We will accelerate the clinical process of ADC189, and strive to become the first class 1 innovative anti-influenza drug independently developed and approved for marketing in China, bringing new solutions that can be "healed" and "reached" for patients in China and the world
    .


    " Dr.


    The Antikang bioscientist team has long focused on the research and development of small molecule innovative drugs in the field of anti-infection
    .


    Since the establishment of the company, a pragmatic and efficient R&D team has established a R&D pipeline containing 8 drug candidates in only 2 years


    It is understood that Antikang Bio is currently conducting a round A financing of up to 60 million yuan, and Clearing Capital is acting as the exclusive financial advisor for this financing


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.